SuperworthSAB Biotherapeutics shares outstanding SABS
Diluted shares outstanding, averaged over each quarter, from 2021.
- Latest quarter, to Jun 30, 2026
- 79.8M
- On a year earlier
- +758.1%
- more shares
SAB Biotherapeutics had 79.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 758.1% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 47.7M | +413% |
| FY2024 | 9.3M | +38% |
| FY2023 | 6.7M | +50% |
| FY2022 | 4.5M | +43% |
| FY2021 | 3.1M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 79.8M | +758% | |
| Q1 FY26 | 53.6M | +476% | |
| Q4 FY25 | 47.7M | +413% | |
| Q3 FY25 | 77.9M | +741% | |
| Q2 FY25 | 9.3M | +0% | |
| Q1 FY25 | 9.3M | +1% | |
| Q4 FY24 | 9.3M | +38% | |
| Q3 FY24 | 9.3M | +77% | |
| Q2 FY24 | 9.3M | +84% | |
| Q1 FY24 | 9.2M | +83% | |
| Q4 FY23 | 6.7M | +50% | |
| Q3 FY23 | 5.2M | +22% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on SAB Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.